Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Mar 27, 2025; 17(3): 101061
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.101061
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.101061
Table 1 Comparison of clinical data between sphincter-preserved and sphincter-unpreserved groups, n (%)
Factors | Sphincter-preserved group | Sphincter-unpreserved group | Statistics | P value |
Age (years) | 67 (59, 72) | 65 (57, 73) | 0.719 | 0.472 |
Sex | 0.001 | 0.985 | ||
Male | 98 (65.3) | 19 (65.5) | ||
Female | 52 (34.7) | 10 (34.5) | ||
Residence | 3.951 | 0.047 | ||
Rural | 63 (42.0) | 18 (62.1) | ||
Urban | 87 (58.0) | 11 (37.9) | ||
BMI (kg/m2) | 22.8 ± 3.2 | 22.5 ± 3.3 | 0.587 | 0.558 |
Time since onset of first symptoms or diagnosis (months) | 2 (1, 6) | 3 (2, 7) | 1.225 | 0.220 |
Duration of preoperative care (days) | 7 (5, 9) | 7 (6, 10) | 0.925 | 0.355 |
Preoperative bowel preparation time (days) | 6 (4, 7) | 6 (5, 7) | 0.731 | 0.465 |
Colonic polyps | 72 (48.0) | 8 (27.6) | 4.097 | 0.043 |
Rectal polyps | 20 (13.3) | 1 (3.4) | 1.438 | 0.230 |
Tumours with bleeding | 107 (71.3) | 20 (69.0) | 0.066 | 0.797 |
Tumours causing obstruction | 22 (14.7) | 1 (3.4) | 1.821 | 0.177 |
Neoadjuvant chemotherapy | 20 (13.3) | 10 (34.5) | 6.349 | 0.012 |
Preoperative radiotherapy | 16 (10.7) | 7 (24.1) | 2.827 | 0.093 |
History of hypertension | 53 (35.3) | 12 (41.4) | 0.384 | 0.535 |
Diabetes mellitus | 22 (14.7) | 7 (24.1) | 0.984 | 0.321 |
Coronary artery disease | 24 (16.0) | 2 (6.9) | 0.972 | 0.324 |
Peripheral vascular lesions of the lower extremities | 11 (7.3) | 5 (17.2) | 1.840 | 0.175 |
History of previous abdominal surgery | 41 (27.3) | 6 (20.7) | 0.554 | 0.457 |
History of recent aspirin use | 22 (14.7) | 3 (10.3) | 0.104 | 0.747 |
Smoking history | 26 (17.3) | 6 (20.7) | 0.186 | 0.666 |
Alcohol consumption history | 20 (13.3) | 3 (10.3) | 0.019 | 0.891 |
Preoperative hypoproteinemia | 17 (11.3) | 5 (17.2) | 0.334 | 0.563 |
Preoperative anemia | 13 (8.7) | 5 (17.2) | 1.141 | 0.285 |
Pelvic effusion | 48 (32.0) | 8 (27.6) | 0.220 | 0.639 |
Clinical stage | 1.383 | 0.240 | ||
0/I/II | 95 (63.3) | 15 (51.7) | ||
III/IV | 55 (36.7) | 14 (48.3) | ||
Tumour T stage | 0.030 | 0.863 | ||
Tis/T1/T2 | 49 (32.7) | 9 (31.0) | ||
T3/T4 | 101 (67.3) | 20 (69.0) | ||
N stage | 0.390 | 0.532 | ||
N- | 87 (58.0) | 15 (51.7) | ||
N+ | 63 (42.0) | 14 (48.3) | ||
Degree of tumour differentiation | 4.003 | 0.144 | ||
Medium differentiation | 124 (82.7) | 22 (75.9) | ||
High differentiation | 17 (11.3) | 2 (6.9) | ||
Low differentiation | 9 (6.0) | 5 (17.2) | ||
Mucinous adenocarcinoma | 14 (9.3) | 7 (24.1) | 3.813 | 0.051 |
Vascular invasion | 38 (25.3) | 7 (24.1) | 0.018 | 0.892 |
Nerve invasion | 75 (50.0) | 22 (75.9) | 6.548 | 0.011 |
Preoperative fever of ≥ 37 °C | 31 (20.7) | 10 (34.5) | 2.627 | 0.105 |
ASA grading | 0.283 | 0.595 | ||
I/II | 112 (74.7) | 23 (79.3) | ||
III/IV | 38 (25.3) | 6 (20.7) | ||
Tumour height | 69.652 | < 0.001 | ||
Upper rectum | 55 (36.7) | 1 (3.4) | ||
Middle rectum | 73 (48.6) | 2 (6.9) | ||
Lower rectum | 22 (14.7) | 26 (89.7) | ||
Maximum transverse tumour diameter (cm) | 3.5 (2.8, 4.6) | 3.8 (3.2, 4.4) | 0.502 | 0.616 |
CEA (ng/mL) | 3.25 (1.60, 10.55) | 5.79 (3.21, 10.41) | 2.444 | 0.015 |
CA19-9 (ng/mL) | 13.65 (8.02, 21.43) | 21.61 (12.28, 24.80) | 2.299 | 0.022 |
ALB (g/L) | 38.0 ± 4.1 | 38.0 ± 3.8 | 0.001 | 0.999 |
GLU (mmol/L) | 4.89 (4.35, 5.63) | 5.24 (4.61, 5.33) | 0.849 | 0.396 |
Potassium (mmol/L) | 3.9 (3.7, 4.2) | 3.9 (3.8, 4.2) | 0.527 | 0.598 |
PT-T (second) | 12.3 (11.6, 12.9) | 12.3 (11.7, 12.6) | 0.031 | 0.975 |
DD (mg/L) | 0.77 (0.62, 1.11) | 0.88 (0.72, 1.72) | 1.874 | 0.061 |
WBC (109/L) | 5.38 (4.54, 6.41) | 5.75 (5.07, 5.82) | 1.106 | 0.269 |
PLT (109/L) | 203 (166, 239) | 204 (188, 222) | 0.672 | 0.502 |
Table 2 Logistic regression analysis of sphincter preservation in laparoscopic radical rectal cancer surgery
Variable | β | P value | OR | 95%CI |
Residence | 1.046 | 0.131 | 2.845 | 0.732-11.063 |
Colonic polyps | -2.207 | 0.006 | 0.110 | 0.023-0.535 |
Neoadjuvant chemotherapy | 1.848 | 0.302 | 6.347 | 0.190-211.759 |
Preoperative radiotherapy | 0.807 | 0.674 | 2.241 | 0.052-95.916 |
Mucinous adenocarcinoma | 2.504 | 0.009 | 12.230 | 1.847-80.999 |
Nerve invasion | 1.836 | 0.012 | 6.272 | 1.499-26.247 |
Tumour height | ||||
Upper rectum | Refence | |||
Middle rectum | 5.292 | < 0.001 | 198.820 | 13.665-2892.686 |
Lower rectum | 5.593 | < 0.001 | 268.639 | 22.203-3250.284 |
CEA | -0.021 | 0.390 | 0.980 | 0.935-1.027 |
CA19-9 | -0.015 | 0.240 | 0.985 | 0.961-1.010 |
DD | -0.013 | 0.755 | 0.987 | 0.910-1.071 |
- Citation: Liu JR, Zhang J, Duan XL. Risk factors influencing sphincter preservation in laparoscopic radical rectal cancer surgery. World J Gastrointest Surg 2025; 17(3): 101061
- URL: https://www.wjgnet.com/1948-9366/full/v17/i3/101061.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i3.101061